皓元医药：2025年度净利润2.48亿元，同比增长22.91%

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating a robust business strategy focused on international expansion and innovation [1] Financial Performance - The company achieved total operating revenue of 2.868 billion yuan, representing a year-on-year increase of 26.35% [1] - The net profit attributable to the parent company was 248 million yuan, up 22.91% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses reached 252 million yuan, reflecting a substantial year-on-year growth of 40.82% [1] Business Strategy - The company strengthened its brand and overseas business team, actively developing international partnerships and expanding into overseas markets [1] - Emphasis was placed on innovation-driven strategies and quality management, leading to strong growth in the life sciences reagent business [1] - The revenue share from the life sciences reagent business increased significantly compared to 2024, with a focus on cutting-edge scientific research and new drug development [1]